吉西他滨联合顺铂治疗远处转移性鼻咽癌的效果观察

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (30 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the short-term efficacy and adverse reaction of Gemcitabine plus Cisplatin(GP regimen)in the treatment of metastatic nasopharyngeal carcinoma(NPC).Methods 46 patients with metastatic NPC treated in our hospital from July 2015 to May 2016 were randomly divided into observation group and control group,23 cases in each group.Ⅰn the observation group,GP regimen was used for intravenous drip chemotherapy,with Gemcitabine 1000 mg/m2,d1,d8;Cisplatin 25 mg/m2,d1-d3.Patients in the control group were given Cisplatin 25 mg/m2,d1-d3;FU 0.75 mg/m2, d1-d5.21 days for a cycle,the whole chemotherapy contained 4 cycles.The therapeutic effect and side effects of the patients were observed.Results The objective effective rate and disease control rate in the observation group was significantly higher than that in the control group(78.26%vs 43.48%;95.65%vs 69.56%)(P＜0.05).The main side effects of two groups were white blood cell reduction,thrombocytopenia,anemia,nausea and vomiting,and elevated aminotransferase.The two groups had no significant difference in the severity of toxicity(P＞0.05).Conclusion GP regimen has a good short-term effect on metastatic NPC,and the toxicity is mild,which can be used as first-line chemotherapy for metastatic NPC.

Key words： Gemcitabine Cisplatin Nasopharyngeal carcinoma Chemotherapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Fan
	YI Jun

Cite this article:

WANG Fan,YI Jun. Clinical efficacy of GP regimen in the treatment of distant metastatic nasopharyngeal carcinoma[J]. 中国当代医药, 2016, 23(30): 72-74.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I30/72

[1]	吕建广，梁理娟，符伟平，等.64排螺旋CT对鼻咽癌的诊断价值[J].中国当代医药，2015，22（30）：71-73.
[2]	刘玉猛，陆小军，雷风，等.局部晚期鼻咽癌放疗与化疗综合治疗的生存分析[J].中国当代医药，2013，20（6）：57-58.
[3]	Foo KF，Tan EH，Leong SS，et al.Gemcitabine in meta static nasopharyngeal carcinoma of the undifferentiated type[J]. Ann Oncol，2002，13（1）：150-156.
[4]	Peters GJ，Bergman AM，Ruiz Van Hapren VW，et al.Ⅰnteraction between cisplatin and gemcitabine in vitro and in vivo[J].Semin Onco1，1995，22（Suppl 11）：72-79.
[5]	WHO.WHO handbook for reporting results of cancer treatment[M].OffsetPublicationNo.48.Geneva（Switzeland）：World Health Organization，1979.
[6]	Trotti A，Byhardt R，Stetz J，et al.Common toxicity criteria：version 2.0.an improved reference for grading the acute effects of cancer treatment：impact on radiotherapy[J].Ⅰnt J Radiat Oncol Biol Phys，2000，47（1）：13-47.
[7]	顾仲义，魏青，黄克伟，等.PF方案化放疗治疗晚期鼻咽癌的远期疗效[J].中华肿瘤杂志，1997，19（5）：392-393.
[8]	崔建东，张羽，龙桂宁，等.奈达铂联合氟尿嘧啶治疗转移性鼻咽癌的临床观察[J].实用临床医药杂志，2012，16（23）：104.
[9]	张力，姜文奇，徐瑞华，等.紫杉醇（Paclitaxel）治疗晚期鼻咽癌的临床研究[J].癌症，2000，19（8）：811-813.
[10]	武变荣，沈存芳，骆玉霜.吉西他滨治疗晚期胆管癌临床疗效评价[J].现代肿瘤医学，2015，23（15）：2173-2175.
[11]	王羽，陈国健，邓利秾，等.吉西他滨联合顺铂一线治疗复发及转移头颈部癌的疗效分析[J].当代医学，2012，18（36）：143-144.
[12]	Nagourney RA，Evans SS，Makalinao AJ，et al.Gemcitabine activity in primary cultures of human cancer（abstract 2161）[J].Proc Am Assoc Cancer，1996，37：318.
[13]	Ngan PK，Yiu HH，Lan WH，et al.Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma：report of a phaseⅡstudy[J].Ann Oncol，2002，13（8）：1252-1258.
[14]	沈祝苹，江子芳，胡国珍，等.吉西他滨调整方案治疗晚期非小细胞肺癌的毒副作用观察和护理[J].中国农村卫生事业管理，2013，33（6）：668-670.
[15]	Karaoglu A，Arslan UY，Ozkan M，et al.Efficacy and toxicity of gemcitabine and pegylated liposomal Doxorubicin in recurrent platinum-resistant/refractory epithelial ovarian cancer[J].Asian Pac J Cancer Prev，2009，10（1）：63-66.